Dalton Pharma Services has received a three-year renewal and license amendment from Health Canada under the Cannabis Regulations. This amendment authorizes Dalton to sell cGMP cannabis derived products on a “business-to-business” basis to Federal License holders.
 
With its combined Health Canada cGMP and Cannabis licenses, Dalton is positioned to test, develop, produce, and supply cGMP cannabinoids to support the delivery and commercial success of medical cannabinoid products.
 
“This important milestone enables Dalton to transfer finished cGMP cannabis products to licensed dealers,” said Peter Pekos, chief executive officer, Dalton Pharma. “Dalton’s Health Canada licensed cGMP pharmaceutical manufacturing facility is now supporting the imminent commercial launch of CardiolRx, a high concentration pharmaceutically-produced cannabidiol formulation developed through our exclusive partnership with Cardiol Therapeutics, and providing innovative pharmaceutical cannabis products and services to the medical cannabis industry. Dalton is excited to be able to support the industry-wide need for cGMP compliant cannabis manufacturing capabilities to supply our clients’ products to patients.”